The Zhitong Finance App learned that on Friday, Trex Bio (TRXB.US) entered the US stock market. As of press release, the stock had fallen more than 1.3% to $13.805. The IPO price is $14. TrEx Bio is a clinical-stage biopharmaceutical company dedicated to developing drugs that enhance regulatory T cell (Treg) function in inflamed human tissues. The goal is to restore immune balance and repair barrier damage rather than broadly suppressing the immune system. Its Deep Biology platform can map the function of Tregs in human skin, gut, and lung tissue to identify targets and verify them through proprietary in vitro Tregs models and high-throughput functional detection methods.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.